| Literature DB >> 35209167 |
José Ignacio Laines-Hidalgo1, José Armando Muñoz-Sánchez1, Lloyd Loza-Müller1, Felipe Vázquez-Flota1.
Abstract
Benzophenanthridines belong to the benzylisoquinolic alkaloids, representing one of the main groups of this class. These alkaloids include over 120 different compounds, mostly in plants from the Fumariaceae, Papaveraceae, and Rutaceae families, which confer chemical protection against pathogens and herbivores. Industrial uses of BZD include the production of environmentally friendly agrochemicals and livestock food supplements. However, although mainly considered toxic compounds, plants bearing them have been used in traditional medicine and their medical applications as antimicrobials, antiprotozoals, and cytotoxic agents have been envisioned. The biosynthetic pathways for some BZD have been established in different species, allowing for the isolation of the genes and enzymes involved. This knowledge has resulted in a better understanding of the process controlling their synthesis and an opening of the gates towards their exploitation by applying modern biotechnological approaches, such as synthetic biology. This review presents the new advances on BDZ biosynthesis and physiological roles. Industrial applications, mainly with pharmacological approaches, are also revised.Entities:
Keywords: alkaloids; benzophenanthridines; benzylisoquinoline; natural products; specialized metabolism
Mesh:
Substances:
Year: 2022 PMID: 35209167 PMCID: PMC8876366 DOI: 10.3390/molecules27041378
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structure of the different benzophenathridines (BZD).
Figure 2Chemical structure of the BZD analyzed in this review.
A few plants bearing BZD alkaloids and their traditional medicinal uses.
| Plant Species | Applications | References |
|---|---|---|
| Antiprotozoals: to dissolve eye cataracts, to remove warts, and to treat skin infections | [ | |
| Skin, liver, and eye diseases; antiparasitic | [ | |
| Analgesic for chest pain, post-partum blood stasis, and spleen and stomach stasis | [ | |
| Anti-inflammatory and antimicrobial activities | [ | |
| Sedative, anxiolytic, analgesic, soporific, spasmolytic, diuretic, and diaphoretic | [ | |
| To treat cold and congestion, sore throats, emetic, abdominal cramps, lumps, wound infections, and rheumatism | [ |
Figure 3Biosynthetic pathways leading to sanguinarine. TyDC, l-tyrosine decarboxylase; NCS, s-norcoclaurine synthase; 6OMT, s-norcoclaurine-6-O-methyltransferase; BBE, reticuline oxidase: berberine bridge enzyme; CheSyn, cheilanthifoline synthase; StySyn, stylopine synthase; TNMT, s-tetrahydroprotoberberine N-methyltransferase; MSH, methyltetrahydroprotoberberine 14-monooxygenase; P6H, protopine 6-hydroxylase; DBOX, dihydrobenzophenanthridine oxidase; and SanR, sanguinarine reductase.
Enzymes involved in sanguinarine biosynthesis, describing reaction catalyzed and subcellular localization. Data were collected from UniProt Beta (https://beta.uniprot.org/ (accessed on 12 December 2021)).
| Enzyme and EC Number | Function | Subcellular Localization | Organisms amd Acc. Number |
|---|---|---|---|
| Decarboxylates of | Cytosol | ||
| Condenses dopamine and 4-HPDA, producing | Endoplasmic reticulum lumen and vacuole | ||
| Transfers a methyl group from SAM to | Membrane integral protein | ||
| Reticuline oxidase: berberine bridge enzyme | Converts | Cytoplasmic vesicles | |
| Cheilanthifoline synthase (CheSyn) EC:1.14.19.65 | Converts | Endoplasmic reticulum membrane | |
| Stylopine synthase | Forms a methylenedioxy bridge on ring A (2,3 position), transforming | Smooth endoplasmic reticulum membrane | |
| Converts stylopine, canadine, and tetrahydropalmatine to their corresponding N-methylated products | Cytosol | ||
| Methyltetrahydroprotoberberine 14-monooxygenase (MSH) EC:1.14.14.97 | Transforms, by oxidation, N-methylstylopine and N-methylcanadine into protopine and allocryptopine, respectively | Membranal protein | |
| Protopine 6-hydroxylase (P6H) EC:1.14.14.98 | Converts protopine and allocryptopine to dihydrosanguinarine and dihydrochelerythrine by hydroxylation at position 6 | Endoplasmic reticulum membrane | |
| Dihydrobenzophenanthridine oxidase (DBOX) | Catalyzes a two-electron oxidation of dihydrosanguinarine, forming sanguinarine | Endoplasmic reticulum | |
| Sanguinarine reductase (SanR) EC:1.3.1.107 | Catalyzes reduction of benzophenanthridines, preferentially sanguinarine, to the dihydroalkaloids; involved in detoxifying the phytoalexins produced by plant itself | Vacoule |
Pharmacological effects of sanguinarine and related alkaloids.
| Alkaloid | Effects | Mechanism | References |
|---|---|---|---|
| Sanguinarine (I) | Antimicrobial | Halts formation of contracting belt by binding to the FtsZ protein | [ |
| Interferes with carbohydrate metabolisms by inhibiting glucose transport and the 2-ketogluconate pathway | |||
| Increases sensitivity to β-lactam antibiotics | |||
| Antiretroviral | Inhibits transcriptase reverse | [ | |
| Anticancer | Cytotoxic | [ | |
| Anti-inflammatory | Reduces the release of proinflammatory cytokines TNF-α; IL-1β; and IL-6 | [ | |
| Chelerythrine (III) | Adjuvant in COVID-19 treatment | Prevents hyper-inflammatory immune response regulating signaling pathways mediated by Nrf2, NF-κB, and p38 MAPK | [ |
| Reduces protein kinase C-α/-β inhibitory activity, preventing cerebral vasospasm, eryptosis, and pulmonary inflammation and fibrosis | |||
| Antiviral | Viral RNA-intercalation | [ | |
| Anticancer | Reduces phosphorylation of ERK and Akt, downplaying the activation of p53, B-cell Bcl-2, caspases, and PARP | [ | |
| Cheilanthifoline (IV) | Anti-inflammatory | Reduces the release of proinflammatory cytokines and anti-AChE | [ |
| Antimicrobial | Hinders expression of MRSA genes and disrupts membrane integrity | [ |